Cellectis (NASDAQ: CLLS) furnishes nine-month 2025 interim report on Form 6-K

Rhea-AI Filing Summary

Cellectis S.A. has filed a Form 6-K to make its interim report for the nine-month period ended September 30, 2025 available to investors. The report is furnished as Exhibit 99.1.

This interim report is also incorporated by reference into Cellectis’ existing Form F-3 and Form S-8 registration statements, meaning those shelf and equity compensation registrations now include the updated nine-month 2025 information.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

Date of Report: November 7, 2025

Commission File Number: 001-36891

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry

75013 Paris, France

+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Cellectis S.A.

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of Cellectis S.A. on Form F-3 (Nos. 333-284302 and 333-288491) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760, 333-273777, 333-284301 and 333-290218), to the extent not superseded by documents or reports subsequently filed.

EXHIBIT INDEX

Exhibit		Title
99.1		Cellectis S.A.’s interim report for the nine-month period ended September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CELLECTIS S.A. (Registrant)
November 7, 2025	By:	/s/ André Choulika
		André Choulika
		Chief Executive Officer

FAQ

What did Cellectis (CLLS) file in this Form 6-K?

Cellectis filed a Form 6-K to provide its interim report for the nine-month period ended September 30, 2025. The report is attached as Exhibit 99.1 and updates investors on this period.

Which period does Cellectis’ interim report on the Form 6-K cover?

The interim report furnished by Cellectis covers the nine-month period ended September 30, 2025. This timeframe provides an update between full-year reports for investors and other stakeholders.

How is this Cellectis (CLLS) Form 6-K used in existing registrations?

The information in this Form 6-K, including Exhibit 99.1, is incorporated by reference into Cellectis’ Form F-3 and Form S-8 registration statements, updating those documents with the interim nine-month 2025 information.

Which Cellectis registration statements are updated by this Form 6-K?

This Form 6-K and Exhibit 99.1 are incorporated by reference into Cellectis’ Form F-3 registration statements numbered 333-284302 and 333-288491, and multiple Form S-8 statements listed in the filing text.

Who signed the Cellectis (CLLS) Form 6-K?

The Form 6-K was signed on behalf of Cellectis S.A. by André Choulika, the company’s Chief Executive Officer, confirming the company’s authorization of the submission.